Elanco’s acquisition of Bayer AG’s animal health business not opposed (subject to undertakings)
The ACCC has announced it will not oppose Elanco’s acquisition of Bayer AG’s animal health business.
The ACCC noted that it ‘had concerns about the effect of the acquisition in the markets for sheep lice treatments, and worming treatments for cats and dogs’. To alleviate concerns Elanco provided a court-enforceable undertaking to divest four animal parasite treatment brands. ACCC Deputy Chair Mick Keogh said:
“Elanco’s acquisition was likely to raise competition concerns in the supply of sheep lice treatments. Without the divestment, Elanco would have significantly increased its market share in the supply of sheep lice treatments”